FEMY Femasys Inc
Company Analysis
Latest News
Femasys partners with UNC Health, offering fertility treatments without specialist referrals
Femasys Inc. partnered with UNC Health to distribute fertility products across North Carolina OB/GYN locations. The collaboration allows UNC Health providers...
🔴 Femasys is trading 6.16% down today — no clear catalyst identified
Femasys is trading at $2.74, down -6.16%, with no clear company-specific catalyst identified. - The latest major catalyst was the August 19 FDA modular PMA...
🔴 Femasys is trading 6.76% down in pre-market, possibly reflecting profit-taking
Femasys is trading 6.76% down at $2.76, possibly reflecting profit-taking after recent gains, though no company-specific catalyst has been confirmed. - No...
🟢 Femasys is trading 11.72% up today after FDA approval of modular PMA pathway
Femasys is trading 11.72% up now at $3.05 after the FDA approved a modular PMA pathway for investigational FemBloc. - The pathway lets the FDA review...
🟢 Femasys is trading 5% up today after FDA approved modular PMA pathway for FemBloc
Femasys is trading 5% up now at $2.87 after the FDA approved a modular PMA pathway for investigational FemBloc, its non-surgical permanent birth-control...
🔴 Femasys is trading 8.55% down in pre-market after investors took profits following FDA pathway approval
Femasys is trading 8.55% down in pre-market at $2.50 after investors took profits following the FDA’s modular PMA pathway approval for investigational...
🔴 Femasys is trading 6.27% down today as investors take profits after FDA pathway rally
Femasys is trading 6.27% down today at $2.54 as investors take profits following yesterday's significant rally. - Femasys surged 23.18% on August 19 after the...
🔴 Femasys is trading 10.68% down in pre-market after an August 19 rally
Femasys is trading at $2.42, down -10.68%, following a sharp August 19 rally after the FDA approved a modular PMA pathway for FemBloc. - The decision allows...
Femasys Gets a Regulatory Green Light for Its Birth-Control Device — But Can a $8 Million Company Turn Paperwork Into Profits?
Shares of Femasys (FEMY) sank -7.7% to $2.50 in pre-market trading on August 20, one day after a euphoric rally that saw the stock spike as high as $3.69...
🔴 Femasys is trading 7.75% down in pre-market after profit-taking following FDA’s modular PMA pathway approval
Femasys is trading at $2.50 (-7.75%) in pre-market on August 20, 2026, with weakness appearing to reflect profit-taking after FDA approval of a modular PMA...
🔴 Femasys is trading 6.27% down in after-hours trading amid apparent profit-taking after FDA pathway approval
Femasys is trading at $2.54, down 6.27%, with the after-hours decline appearing to reflect profit-taking after the FDA approved a modular PMA pathway for...
Femasys Wins FDA Rolling Review for FemBloc, Expediting Approval Path
Femasys Inc. received FDA approval for a modular premarket approval (PMA) submission for its FemBloc permanent birth control device. This allows the company to...
🟢 Femasys is trading 24.05% up today after positive Moderna and Merck melanoma-vaccine results
Femasys is trading 24.05% up now at $2.73, primarily as biotechnology shares rallied after positive Moderna and Merck Phase 3 melanoma-vaccine results. - The...
🔴 Femasys is trading 5% down today after Q2 sales fell 18.9% year over year
Femasys is trading 5% down at $2.17 after investors digested the August 14, 2026 quarterly results, with Q2 sales falling 18.9% year over year to $331,827...
Femasys second quarter 2026 revenue of $0.33M missed estimates significantly despite subsequent $30M financing
Femasys reported a substantial miss on top and bottom-line results for the second quarter 2026, with revenue declining nearly 19% year-over-year. The results...
🔴 Femasys is trading 5.5% down today as $30 million placement raises dilution concerns
Femasys is trading at $2.22, down -5.53%, as its announced $30 million private placement raises dilution concerns. - The financing includes shares and...
Femasys Inc Q2 2026 Earnings Preview: What Analysts Expect on August 14, 2026
Analysts expect Femasys Inc to report a consensus revenue of $1.68 million and a net loss per share of $0.10 for the second quarter, while the current stock...
Femasys Locks Down Key Patents and Fresh Cash — But Can a Micro-Cap Birth Control Startup Translate IP Into Revenue?
Shares of Femasys jumped 14% to $2.68 after the Atlanta-based women's health company disclosed new U.S. and international patents covering the core...
🟢 Femasys is trading 14% up today in after-hours trading after new U.S. and international FemBloc patents
Femasys is trading at $2.68, up +13.96% after announcing new U.S. and international patents protecting FemBloc’s blended-polymer component on August 12,...
🟢 Femasys is trading 6.6% up today with no company-specific catalyst identified
Femasys is trading 6.6% up at $2.50, amid a stronger broader market, with no new company-specific announcement explaining the August 12, 2026 move...